SE0104140D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
SE0104140D0
SE0104140D0 SE0104140A SE0104140A SE0104140D0 SE 0104140 D0 SE0104140 D0 SE 0104140D0 SE 0104140 A SE0104140 A SE 0104140A SE 0104140 A SE0104140 A SE 0104140A SE 0104140 D0 SE0104140 D0 SE 0104140D0
Authority
SE
Sweden
Prior art keywords
novel compounds
pharmaceutical compositions
therapy
preparing
processes
Prior art date
Application number
SE0104140A
Other languages
English (en)
Swedish (sv)
Inventor
Andrew Pape
Andrew Thomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104140A priority Critical patent/SE0104140D0/xx
Publication of SE0104140D0 publication Critical patent/SE0104140D0/xx
Priority to UA20040705367A priority patent/UA78259C2/uk
Priority to TW091134937A priority patent/TWI324152B/zh
Priority to NZ533130A priority patent/NZ533130A/en
Priority to PL02369528A priority patent/PL369528A1/xx
Priority to ES02791165T priority patent/ES2323125T3/es
Priority to SI200230824T priority patent/SI1456182T1/sl
Priority to PCT/SE2002/002221 priority patent/WO2003048133A1/en
Priority to EP02791165A priority patent/EP1456182B1/en
Priority to HU0401855A priority patent/HUP0401855A3/hu
Priority to AT02791165T priority patent/ATE425150T1/de
Priority to KR1020047008612A priority patent/KR100930558B1/ko
Priority to RU2004121029/04A priority patent/RU2317291C2/ru
Priority to BR0214605-3A priority patent/BR0214605A/pt
Priority to IL16237602A priority patent/IL162376A0/xx
Priority to JP2003549325A priority patent/JP4347051B2/ja
Priority to AU2002365864A priority patent/AU2002365864B2/en
Priority to DE60231542T priority patent/DE60231542D1/de
Priority to DK02791165T priority patent/DK1456182T3/da
Priority to US10/497,744 priority patent/US7521453B2/en
Priority to MXPA04005347A priority patent/MXPA04005347A/es
Priority to CNB02827802XA priority patent/CN1289486C/zh
Priority to PT02791165T priority patent/PT1456182E/pt
Priority to CA2467838A priority patent/CA2467838C/en
Priority to MYPI20024549A priority patent/MY135705A/en
Priority to ARP020104747A priority patent/AR037736A1/es
Priority to ZA200404223A priority patent/ZA200404223B/en
Priority to CO04052141A priority patent/CO5590919A2/es
Priority to IS7294A priority patent/IS7294A/is
Priority to IL162376A priority patent/IL162376A/en
Priority to EGNA2004000039 priority patent/EG24930A/xx
Priority to NO20042872A priority patent/NO327502B1/no
Priority to HK05100089.7A priority patent/HK1067631A1/xx
Priority to US12/359,541 priority patent/US20090131463A1/en
Priority to CY20091100558T priority patent/CY1109101T1/el
Priority to US13/313,097 priority patent/US20120095011A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0104140A 2001-12-07 2001-12-07 Novel Compounds SE0104140D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE0104140A SE0104140D0 (sv) 2001-12-07 2001-12-07 Novel Compounds
UA20040705367A UA78259C2 (en) 2001-12-07 2002-03-12 Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i)
TW091134937A TWI324152B (en) 2001-12-07 2002-12-02 Pyrimidine derivatives and their process for preparation and use as modulators of insulin-like growth factor-1 receptor(igf-1)
CA2467838A CA2467838C (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)
AU2002365864A AU2002365864B2 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (IGF-I)
MXPA04005347A MXPA04005347A (es) 2001-12-07 2002-12-03 Derivados de pirimidina como moduladores del receptor (igf-i) del factor-1 de crecimiento similares a la insulina.
ES02791165T ES2323125T3 (es) 2001-12-07 2002-12-03 Derivados de pirimidina como moduladores del receptor del factor-1 de crecimiento de tipo insulina (igf-i).
SI200230824T SI1456182T1 (sl) 2001-12-07 2002-12-03 Pirimidinski derivati kot modulatorji insulinu podobnega receptorja rastnega faktorja-1 (IGF-I)
PCT/SE2002/002221 WO2003048133A1 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)
EP02791165A EP1456182B1 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)
HU0401855A HUP0401855A3 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-ir), process for their preparation, their use and pharmaceutical compositions containing them
AT02791165T ATE425150T1 (de) 2001-12-07 2002-12-03 Pyrimidinderivate als modulatoren des insulinähnlichen wachstumsfaktor-1-rezeptors (igf-i)
KR1020047008612A KR100930558B1 (ko) 2001-12-07 2002-12-03 인슐린-유사 성장 인자－１ 수용체 (ｉｇｆ－１)의조절제로서의 피리미딘 유도체
RU2004121029/04A RU2317291C2 (ru) 2001-12-07 2002-12-03 Производные пиримидина в качестве модуляторов рецептора инсулинподобного фактора роста 1 (igf-1), фармацевтическая композиция, способы получения (варианты) и применение
BR0214605-3A BR0214605A (pt) 2001-12-07 2002-12-03 Composto, composição farmacêutica, processos para preparar os mesmos, uso de um composto, e, método para tratar câncer, e para modular a atividade do receptor do fator-1 de crescimento semelhante à insulina
IL16237602A IL162376A0 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-ir)
JP2003549325A JP4347051B2 (ja) 2001-12-07 2002-12-03 インスリン様成長因子１受容体（ｉｇｆ−ｉ）のモジュレーターとしてのピリミジン誘導体
NZ533130A NZ533130A (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-I)
DE60231542T DE60231542D1 (de) 2001-12-07 2002-12-03 Chen wachstumsfaktor-1-rezeptors (igf-i)
DK02791165T DK1456182T3 (da) 2001-12-07 2002-12-03 Pyrimidinderivater som modulatorer af insulinlignende vækstfaktor-1-receptor(1GF-1)
US10/497,744 US7521453B2 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-I)
PL02369528A PL369528A1 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)
CNB02827802XA CN1289486C (zh) 2001-12-07 2002-12-03 作为胰岛素样生长因子－1受体(igf－i)调节剂的嘧啶衍生物
PT02791165T PT1456182E (pt) 2001-12-07 2002-12-03 Derivados de pirimidina como moduladores do receptor do factor de crescimento semelhante à insulina-1 (igf-i)
MYPI20024549A MY135705A (en) 2001-12-07 2002-12-04 Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i)
ARP020104747A AR037736A1 (es) 2001-12-07 2002-12-06 Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
ZA200404223A ZA200404223B (en) 2001-12-07 2004-05-28 Pyrimidine derivatives as modulars of insuline-like growth factor-1 receptor (IGF-I).
CO04052141A CO5590919A2 (es) 2001-12-07 2004-06-03 Derivados de pirimidina como moduladores de receptor de factor-1 de crecimiento similara la insulina (igf-1)
IS7294A IS7294A (is) 2001-12-07 2004-06-03 Pýrimídínafleiður sem stillar vaxtarþáttar-1 viðtaka sem líkist insúlíni (IGF-I)
IL162376A IL162376A (en) 2001-12-07 2004-06-06 Pyrimidine derivatives wherein a nitrogen heteroatom is attached at positions 2 and 4 thereof, process for their preparation, pharmaceutical compositions containing them and use of such pyrimidine derivatives in the manufacture of medicaments and as medicaments for modulating insulin-like growth factor-1 receptor activity in a patient
EGNA2004000039 EG24930A (en) 2001-12-07 2004-06-06 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (IGF-I)
NO20042872A NO327502B1 (no) 2001-12-07 2004-07-06 Pyrimidinderivater, fremgangsmate for fremstilling av disse, farmasoytiske preparater innehodende dem og anvendelse av slike for fremstilling av medikamenter for behandling av sykdom
HK05100089.7A HK1067631A1 (en) 2001-12-07 2005-01-06 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)
US12/359,541 US20090131463A1 (en) 2001-12-07 2009-01-26 Novel compounds
CY20091100558T CY1109101T1 (el) 2001-12-07 2009-05-25 Παραγωγα πυριμιδινης ως ρυθμιστες υποδοχεα (igf-i) ινσουλινοειδους αυξητικου παραγοντα-1
US13/313,097 US20120095011A1 (en) 2001-12-07 2011-12-07 Novel compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104140A SE0104140D0 (sv) 2001-12-07 2001-12-07 Novel Compounds

Publications (1)

Publication Number Publication Date
SE0104140D0 true SE0104140D0 (sv) 2001-12-07

Family

ID=20286257

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104140A SE0104140D0 (sv) 2001-12-07 2001-12-07 Novel Compounds

Country Status (33)

Country Link
US (3) US7521453B2 (xx)
EP (1) EP1456182B1 (xx)
JP (1) JP4347051B2 (xx)
KR (1) KR100930558B1 (xx)
CN (1) CN1289486C (xx)
AR (1) AR037736A1 (xx)
AT (1) ATE425150T1 (xx)
AU (1) AU2002365864B2 (xx)
BR (1) BR0214605A (xx)
CA (1) CA2467838C (xx)
CO (1) CO5590919A2 (xx)
CY (1) CY1109101T1 (xx)
DE (1) DE60231542D1 (xx)
DK (1) DK1456182T3 (xx)
EG (1) EG24930A (xx)
ES (1) ES2323125T3 (xx)
HK (1) HK1067631A1 (xx)
HU (1) HUP0401855A3 (xx)
IL (2) IL162376A0 (xx)
IS (1) IS7294A (xx)
MX (1) MXPA04005347A (xx)
MY (1) MY135705A (xx)
NO (1) NO327502B1 (xx)
NZ (1) NZ533130A (xx)
PL (1) PL369528A1 (xx)
PT (1) PT1456182E (xx)
RU (1) RU2317291C2 (xx)
SE (1) SE0104140D0 (xx)
SI (1) SI1456182T1 (xx)
TW (1) TWI324152B (xx)
UA (1) UA78259C2 (xx)
WO (1) WO2003048133A1 (xx)
ZA (1) ZA200404223B (xx)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
KR20120062863A (ko) 2003-07-30 2012-06-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
DE602004032446D1 (de) * 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
AU2004282219C1 (en) * 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
EP1678169B1 (en) 2003-10-17 2009-07-22 Astrazeneca AB 4-(pyrazol-3-ylamino)pyrimidine derivatives for use in the treatment of cancer
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
ATE384700T1 (de) 2004-03-12 2008-02-15 Analytecon Sa Tetrahydroisochinolin- und tetrahydrobenzazepin derivative als igf-1r inhibitoren
JP2008502595A (ja) * 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
SG163576A1 (en) 2004-04-02 2010-08-30 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
DE102004022897A1 (de) * 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
ES2375735T3 (es) 2005-02-04 2012-03-05 Astrazeneca Ab Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
JP2008540335A (ja) * 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
US20080287437A1 (en) * 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
CA2620174A1 (en) 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
PT1945631E (pt) * 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US8343918B2 (en) * 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
AU2007257701A1 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
MX2008016523A (es) * 2006-06-30 2009-01-19 Astrazeneca Ab Derivados de pirimidina utiles en el tratamiento de cancer.
WO2008005538A2 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
EP2155742A1 (en) * 2007-04-18 2010-02-24 AstraZeneca AB 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer
UA99459C2 (xx) * 2007-05-04 2012-08-27 Астразенека Аб ПОХІДНІ 9-(ПІРАЗОЛ-3-ІЛ)-9H-ПУРИН-2-АМІНУ І 3-(ПІРАЗОЛ-3-ІЛ)-3H-ІМІДАЗО$4,5-b]ПІРИДИН-5-АМІНУ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ РАКУ$ПРОИЗВОДНЫЕ 9-(ПИРАЗОЛ-3-ИЛ)-9H-ПУРИН-2-АМИНА И 3-(ПИРАЗОЛ-3-ИЛ)-3H-ИМИДАЗО$4,5-b]ПИРИДИН-5-АМИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА
US20100204231A1 (en) * 2007-05-04 2010-08-12 Astrazeneca Ab Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2009019518A1 (en) * 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
KR20110017445A (ko) * 2008-06-11 2011-02-21 아스트라제네카 아베 암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체
DE102008041214A1 (de) 2008-08-13 2010-02-18 Bayer Cropscience Ag N-substituierte Azinylakyl-azincarboxamide und deren Analoge
CA2737217A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783656A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2011113861A2 (de) 2010-03-18 2011-09-22 Bayer Cropscience Ag Aryl- und hetarylsulfonamide als wirkstoffe gegen abiotischen pflanzenstress
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
UY33817A (es) * 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
US9796791B2 (en) 2011-04-13 2017-10-24 Eastman Chemical Company Cellulose ester optical films
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
AU2012335541B2 (en) 2011-11-11 2017-07-06 Duke University Combination drug therapy for the treatment of solid tumors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN115124475B (zh) * 2022-07-11 2023-11-10 贵阳学院 一种嘧啶衍生物及其制备方法和用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417402A (en) * 1972-03-30 1975-12-10 Boots Co Ltd Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de) * 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) * 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) * 1992-08-31 1999-04-13 Miguel A. Cacho Automated fluid bed process
WO1997009325A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DK0970369T3 (da) * 1997-03-27 2002-01-28 Glatt Gmbh Fremgangsmåde til overvågning og/eller styring og regulering af en granulerings-, agglomererings-, instantiserings-, coating- og tørringsproces i en fluid bed eller bevæget .....
US6247246B1 (en) * 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
OA11674A (en) 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EA005423B1 (ru) 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422367C (en) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100947185B1 (ko) * 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
EP1423380B1 (en) * 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
AU2002321910A1 (en) * 2001-08-03 2003-02-17 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
US6747461B2 (en) * 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
DK1812440T3 (da) * 2004-11-04 2011-01-31 Vertex Pharma Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
ES2308731T3 (es) * 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
WO2007056221A2 (en) * 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2008016523A (es) * 2006-06-30 2009-01-19 Astrazeneca Ab Derivados de pirimidina utiles en el tratamiento de cancer.
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
US20090131463A1 (en) 2009-05-21
US7521453B2 (en) 2009-04-21
PT1456182E (pt) 2009-05-26
KR20050044698A (ko) 2005-05-12
HUP0401855A2 (hu) 2004-12-28
AU2002365864B2 (en) 2007-08-30
NO20042872L (no) 2004-07-06
AR037736A1 (es) 2004-12-01
KR100930558B1 (ko) 2009-12-09
NO327502B1 (no) 2009-07-27
CA2467838A1 (en) 2003-06-12
DK1456182T3 (da) 2009-06-29
IS7294A (is) 2004-06-03
NZ533130A (en) 2006-11-30
WO2003048133A1 (en) 2003-06-12
CA2467838C (en) 2010-10-12
CO5590919A2 (es) 2005-12-30
AU2002365864A1 (en) 2003-06-17
IL162376A0 (en) 2005-11-20
PL369528A1 (en) 2005-05-02
SI1456182T1 (sl) 2009-08-31
EP1456182A1 (en) 2004-09-15
HK1067631A1 (en) 2005-04-15
CN1617858A (zh) 2005-05-18
TW200409634A (en) 2004-06-16
UA78259C2 (en) 2007-03-15
BR0214605A (pt) 2004-09-14
ATE425150T1 (de) 2009-03-15
RU2004121029A (ru) 2006-01-10
MXPA04005347A (es) 2004-09-27
TWI324152B (en) 2010-05-01
HUP0401855A3 (en) 2008-06-30
US20120095011A1 (en) 2012-04-19
CY1109101T1 (el) 2014-07-02
RU2317291C2 (ru) 2008-02-20
JP4347051B2 (ja) 2009-10-21
IL162376A (en) 2011-07-31
ES2323125T3 (es) 2009-07-07
CN1289486C (zh) 2006-12-13
US20050054638A1 (en) 2005-03-10
EP1456182B1 (en) 2009-03-11
EG24930A (en) 2011-01-11
ZA200404223B (en) 2005-08-29
MY135705A (en) 2008-06-30
DE60231542D1 (de) 2009-04-23
JP2005515998A (ja) 2005-06-02

Similar Documents

Publication Publication Date Title
SE0104140D0 (sv) Novel Compounds
SE0200920D0 (sv) Novel compounds
SE0202539D0 (sv) Compounds
SE0300480D0 (sv) Novel compounds
SE0302811D0 (sv) Novel compounds
SE0103836D0 (sv) Novel compounds
SE0301700D0 (sv) Novel compounds
IS6658A (is) Ný efnasambönd
MY128924A (en) Novel compounds
SE0202133D0 (sv) Novel compounds
HK1048990A1 (en) Novel compounds.
ATE316083T1 (de) Adamantanderivate
SE9904505D0 (sv) Novel compounds
DE602004021472D1 (en) Pyrimiidinverbindungen
TW200616995A (en) Novel compounds
SE0302139D0 (sv) Novel compounds
TW200740781A (en) Novel compounds
TW200604197A (en) New compounds
SE9902765D0 (sv) Novel compounds
SE0101038D0 (sv) Novel compounds
SE0102716D0 (sv) Novel compounds
GB0120461D0 (en) Novel compounds
SE0401763D0 (sv) Compounds
SE0303280D0 (sv) Novel compounds
TW200722418A (en) Novel compounds